10-Q: cbdMD, Inc. Reports Q2 2025 Results, Focuses on Profitability and Strategic Initiatives

cbdMD, Inc. reports its Q2 2025 financial results, highlighting a focus on profitability, strategic initiatives, and addressing compliance with NYSE American continued listing standards.

Summary

• cbdMD, Inc. reported a net loss attributable to common shareholders of $1.48 million for the three months ended March 31, 2025, compared to a net loss of $4.01 million for the same period in 2024.
• Net sales for the quarter were $4.75 million, up from $4.38 million in the prior year.
• The company's operating expenses decreased by $0.69 million to $3.45 million.
• For the six months ended March 31, 2025, the net loss attributable to common shareholders was $2.47 million, compared to $6.01 million in 2024.
• Net sales for the six-month period were $9.86 million, a slight increase from $9.75 million in the prior year.
• The company is focused on optimizing its product portfolio, right-sizing its cost structure, and investing in marketing to improve customer acquisition.
• A reverse stock split at a ratio of one-for-eight was effected on May 6, 2025.
• All outstanding shares of Series A Preferred Stock were converted to Common Stock on May 6, 2025, eliminating accrued dividends.
• The company is working to regain compliance with NYSE American continued listing standards.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments like increased net sales and reduced operating expenses, the company is still operating at a loss and faces challenges related to working capital and compliance with NYSE American listing standards. The sentiment is neutral as the company is taking steps to improve its financial position, but significant risks remain.

Positives

• Net sales increased for the three months ended March 31, 2025.
• Operating expenses decreased for the three months ended March 31, 2025.
• The company launched a new product line (Oasis) and secured distribution agreements.
• The conversion of Series A Preferred Stock and the reverse stock split were completed.

Negatives

• The company reported a net loss attributable to common shareholders of $1.48 million for the three months ended March 31, 2025.
• The company has a working capital deficit of $3.7 million as of March 31, 2025.
• The company received notification from the NYSE American regarding non-compliance with continued listing standards.

Risks

• The company's working capital position may not be sufficient to support daily operations for the next twelve months.
• The company's ability to continue as a going concern is dependent on improving profitability and acquiring additional funding.
• Failure to comply with NYSE American continued listing standards could result in delisting.
• Tariffs on imported packaging materials could increase costs and negatively affect the business.

Future Outlook

Management is focused on optimizing the product portfolio, right-sizing the cost structure, and investing in marketing to improve customer acquisition and achieve profitability.

Management Comments

• Management continues to be very focused on our goal of delivering positive earnings through a combination of optimizing our product portfolio, right-sizing our cost structure and investing in marketing that will provide positive return on customer acquisition.
• We remain focused on growing the Company in a smart, profitable manner along with appropriate cost controls.

Industry Context

The company is operating in the CBD and functional mushroom market, with a focus on hemp-derived solutions. The company is also entering the booming beverage market with its Oasis line of THC-infused social seltzers.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• Without specific competitor data or industry benchmarks, it's difficult to assess cbdMD's performance relative to its peers.
• However, the company's focus on product innovation and expanding revenue channels aligns with common strategies in the consumer packaged goods industry.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split and the conversion of Series A Preferred Stock.
• The company's ability to continue as a going concern could impact employees, suppliers, and creditors.
• Customers may benefit from the company's focus on product innovation and quality.

Next Steps

• The company will continue to focus on optimizing its product portfolio, right-sizing its cost structure, and investing in marketing.
• The company will work to regain compliance with NYSE American continued listing standards.
• The company will continue to explore sales in markets outside of the United States.
• The company will continue to evaluate acquisitions.

Key Dates

Keywords

cbdMD, financial results, CBD, hemp, cannabinoids, Oasis, reverse stock split, preferred stock conversion, NYSE American, listing standards